Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.98% and ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

President Joe Biden wants Medicare and Medicaid to cover weight-loss drugs, a proposal that would expand access to the costly ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

The tech company estimates that its investment will create 100,000 jobs focused on AI and emerging technologies. Canal+'s shares fell on the London Stock Exchange and Havas's stock rose on Euronext ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

If Trump wants to improve Americans’ health, as he says, expanding coverage of weight-loss drugs should be a priority. With ...

For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...